Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Diagnosis & Disease Information
Subcutaneous Daratumumab Linked to Shorter Clinic Times for Patients With Multiple Myeloma
Researchers sought to determine whether a different administration of daratumumab would lead to shorter clinic times for patients with multiple myeloma.
Vagal Nerve Activity as Prognostic Factor for Multiple Myeloma, Relapsed/Refractory DLBCL
Researchers sought to determine if vagal nerve activity could predict overall survival and progression-free survival in patients with R/R DLBCL and MM, respectively.
Second Primary Malignancies After Auto-HSCT Linked to Inferior Outcomes in MM
Multiple myeloma patients who develop second primary malignancies after auto-HSCT have worse survival outcomes, a study suggests.
Factors Linked to Worse CAR-T Outcomes in High-Risk Multiple Myeloma
High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.
Elranatamab Under Review for Relapsed or Refractory Multiple Myeloma
Elranatamab is a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody.
Pano/GBM Plus ASCT Deemed Safe and Effective in High-Risk or Rel/Ref MM
Pano/GBM is safe and effective as conditioning before ASCT in patients with high-risk or relapsed/refractory multiple myeloma, a study suggests.
Body Mass Index Tied to Multiple Myeloma Survival
Decreased survival seen for both underweight and severe obesity in newly diagnosed patients.
MRD Conversion During Maintenance Predicts Progression-Free Survival in Myeloma
Researchers sought to determine whether conversion of MRD status during maintenance would affect risk of disease progression in patients with MM.
Inflammatory-Nutritional Score Helps Predict Survival in New Multiple Myeloma
Nomogram based on inflammatory-nutritional score, other factors exhibits better performance than other staging systems for multiple myeloma.
- Loading...
Loading...
Next post in Myeloma
Loading... 
Loading...